

The Australian Society for Medical Research

ASMR Medical Research Week® June 1 - 8 2007

ASMR Medallist 2007

Professor Axel Ullrich

"From Gene Technology to the Magic Bullet of Cancer Therapy: Is the promise coming true?" Eminent German Scientist, Professor Axel Ullrich in Sydney Tuesday June 5, 2007

A champion of translational research and pioneer in cancer research and treatment, Professor Ullrich of the Max Planck Institute has taken his basic discoveries through to patient therapies including:

- Humulin (human Insulin for the treatment of diabetes), the first therapeutic agent to be developed through gene-based technology and the first biotechnology product ever.
- SUTENT/Sunitinib, for the treatment of Gastro Intestinal Stromal Tumors and Renal Cell Carcinoma
- **Herceptin**, the first gene-targeted treatment aimed at the cells causing breast cancer.

Personalised drug cocktails improving the length and quality of peoples' lives

Professor Ullrich believes the creation of a gene database in the Singapore Onco Genome laboratory will provide a comprehensive picture of the genetics of cancer cell lines and tissues, enabling us to to exploit this knowledge of basic science and develop it into new cancer treatments.

In 2001 Time Magazine Europe has named Professor Ullrich as one of 25 European "tech leaders who are changing how we work, live and play".

> Professor Ullrich will be speaking at the ASMR Medical Research Week® Dinner Tuesday June 6, 2007 Sheraton on the Park

For Interview contact: Dr Emma Parkinson-Lawrence 0400 635 822 or Catherine West on 0415 928 211

Biographical information available from http://www.asmr.org.au/mrw/AxelU.pdf

Fax (02) 9252 0294Email: asmr@world.net, Website: www.asmr.org.au Snr Executive Officer: Catherine West Australian Government



The Australian Society for Medical Research ACN 000599235 - ABN 18 000599235 145 Macquarie Street. Sydney, 2000 Ph: (02) 9256 5450,

